PRODUCTOS ROCHE S.A.Q. e I.

GSK's anti-TIM-3 monoclonal antibody cobolimab failed to improve overall survival in the Phase III COSTAR trial for advanced non-small cell lung cancer patients previously treated with immunotherapy.

IsoBio, Inc. has closed a $5 million Series Seed financing round led by ASP Isotopes Inc. to develop antibody-isotope conjugates (AICs) targeting both validated and novel tumor antigens for cancer treatment.

The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending label expansion of Alhemo (concizumab) to treat severe hemophilia A and moderate/severe hemophilia B without inhibitors.

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Pfizer and BioNTech's LP.8.1-adapted COMIRNATY vaccine targeting XFG and NB.1.8.1 variants.

Roche is considering selling prescription medicines directly to US consumers to lower patient costs, following government pressure to reduce drug prices.

Flatiron Health's international oncology research network has tripled in size over the past year, now encompassing more than 30 partnerships across the UK, Germany, and Japan.

IXICO has deepened its collaboration with the Global Alzheimer's Platform Foundation through an agreement securing full data usage rights to the Bio-Hermes-002 study, one of the most prominent global studies in Alzheimer's disease research.

Roche's pivotal Phase IIb ALIENTO study met its primary endpoint, showing astegolimab reduced annualized exacerbation rate by 15.4% in COPD patients at 52 weeks.

Ryan Richardson will step down as Chief Strategy Officer from BioNTech's Management Board on September 30, 2025, after serving since January 2020.

Moleculin Biotech has appointed Adriano Treve, a 40-year Roche veteran, as Strategic Advisor for partnerships as the company approaches key milestones in its Phase 3 MIRACLE trial.